SLC1A2 and Parkinson disease: Ceftriaxone increased striatal GLT-1 expression, glutamate uptake, and reduced the abnormal involuntary movements known as l-dopa-induced dyskinesia in the 6-hydroxydopamine model of PD (Chotibut et al., 2017).